Aminoester derivatives

A compound of formula (I):

• wherein
• each R1 is the same or different and is independently hydrogen, halogen, (C1-C4) alkyl, (C1-C4) alkoxy, (C1-C4) haloalkyl, hydroxy, —SO2NRIRII, —CN, —NRISO2RIII, —NRIRII, —(CO)NRIRI, or —NRI(CO)RIII, and wherein each said (C1-C4) alkyl is optionally substituted by one or more groups selected from the group consisting of (C3-C7) cycloalkyl, hydroxyl, and —NRIRII and wherein each said (C1-C4) alkoxy is optionally substituted by one or more halogen atoms or (C3-C7) cycloalkyl groups, wherein:
• RI is hydrogen or (C1-C6) alkyl;
• RII is hydrogen or (C1-C6) alkyl;
• RIII is hydrogen or (C1-C6) alkyl;
• n is an integer ranging from 1 to 3;
• each R2 is the same or different and is independently hydrogen, halogen, (C1-C4) alkyl, (C1-C4) alkoxy, (C1-C4)haloalkyl, hydroxy, —SO2NRIRII, —CN, —NRISO2RIII, —NRIRII, —(CO)NRIRII, or —NRI(CO)RIII and wherein eachsaid (C1-C4) alkyl is optionally substituted by one or more groups selected from the group consisting of (C3-C7) cycloalkyl, hydroxyl, and —NRIRII and wherein each said (C1-C4) alkoxy is optionally substituted by one or more halogen atoms or (C3-C7) cycloalkyl groups, wherein:
• RI, RII, and RIII are as defined above;
• m is an integer ranging from 1 to 3;
• each R3 and each R4 are the same or different and is independently H, (C3-C7) cycloalkylcarbonyl, (C1-C6) alkyl optionally substituted by one or more substituents selected from the group consisting of (C3-C7) cycloalkyl and (C5-C7) cycloalkenyl, (C1-C6) haloalkyl, (C3-C7) cycloalkyl, (C5-C7) cycloalkenyl, (C2-C6) alkenyl, and (C2-C6) alkynyl;
• or R3 and R4, together with the interconnecting atoms, form a 2,2-difluoro-1,3-dioxolane ring of formula (r) fused to the phenyl moiety which bears groups —OR3 and —OR4, wherein asterisks indicate carbon atoms shared with such phenyl ring:
• each R5 is the same or different and is independently CN, NO2, CF3, or halogen;
• k is 0 or an integer ranging from 1 to 3;
• x′ is 0 or 1;
• L1 is a bond or —(CH2)p— wherein p is an integer ranging from 1 to 4;
• W1 is a divalent arylene, heteroarylene, or saturated monocyclic heterocycloalkylene group;
• L2 is a bond, —(CH2)q— wherein q is 1 or 2, [1]-(CO)—[X]—(CH2)t-[2], or [1]-(SO2)—[X]—(CH2)t-[2], wherein [1] and [2] represent, respectively the point of attachment of group L2 to the ring W1 and to the chain nitrogen atom, and wherein
• [X] is a bond or a substituted or unsubstituted arylene group;
• t is an integer ranging from 1 to 4;
• R7 is hydrogen or (C1-C4) alkyl optionally substituted by hydroxy or —NR11R12, wherein R11 and R12 are independently hydrogen or (C1-C4) alkyl, or, together with the nitrogen atom to which they are linked, R11 and R12 form a saturated heterocycloalkyl group having an additional heteroatom selected from the group consisting of O, S, and NH;
• and
• A is a nitrogen containing group which is:
• a group (a) which is —(CH2)s—NR8R9 wherein s is an integer ranging from 1 to 4 and R8 and R9 are independently hydrogen or (C1-C4) alkyl;
• or
• a group (b) which is a saturated monocyclic, bicyclic or tricyclic heterocyclic ring system optionally substituted by one or two groups R10 which are at each occurrence independently (C1-C4) alkyl or benzyl;
• and
• wherein W2 is a phenyl ring, L is a bond, and one of R1, which is in the ortho position with respect to L, and R6 are connected to form a ring radical, represented by formula (IB):
• or a pharmaceutically acceptable salt thereof.